EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FAP as a Clinical Biomarker: FAP+ CAFs Orchestrate an Immunosuppressive Stem Cell Niche via the COL1A1/2‐CD44 Axis in Colon Cancer

Qian Ding iD, Qingyan Lu iD

Stem Cells International · 2026-01 · 2026 (1)

DOI: 10.1155/sci/4678145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells International, online erschienen am 06.08.2026. Verfasst von Qian Ding und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Nanjing BenQ Medical Center, Nanjing, Jiangsu, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colon cancer (CC) remains a leading cause of cancer‐related mortality worldwide, driven largely by the complex interactions within the tumor microenvironment (TME). Fibroblast activation protein (FAP) is highly expressed in cancer‐associated fibroblasts (CAFs) and is associated with poor prognosis, yet its role in coordinating immune evasion and cancer stemness remains to be fully elucidated.

Methods

We integrated multiomics data from TCGA and GEO databases, utilizing bulk RNA‐seq and single‐cell RNA‐seq (scRNA‐seq) analyses. Findings were validated via tissue microarray (TMA) immunohistochemistry (IHC). We further employed cell–cell communication analysis, pseudotime trajectory modeling, and the Connectivity Map (CMap) for drug sensitivity prediction and molecular docking.

Results

FAP was significantly upregulated in CC tissues and correlated with advanced clinical stages. scRNA‐seq confirmed that FAP is predominantly expressed in CAFs. Functional analysis revealed that FAP‐high tumors are enriched in extracellular matrix (ECM) remodeling and immunosuppressive pathways. Cell–cell communication analysis identified that FAP+ CAFs interact with T cells and cancer stem cells (CSCs) primarily through the COL1A1/2‐CD44 axis. Specifically, FAP+ CAFs promote the differentiation of naive T cells into regulatory T cells (Tregs) and are positively correlated with various stemness markers, including CD44, ABCG2, and BMI1. Based on these findings, we established a 14‐gene prognostic risk model with robust predictive accuracy (area under the curve [AUC] > 0.64) and identified AS604850 and LY364947 as potential therapeutic agents.

Conclusion

Our study demonstrates that FAP+ CAFs orchestrate a dual‐functional “immunosuppressive stem cell niche” via the COL1A1/2‐CD44 signaling axis. Targeting this FAP‐driven niche provides a promising strategy for overcoming immunotherapy resistance and improving clinical outcomes in CC.

Schlagwörter

Stichwörter der Autor:innen

CD44cancer stem cellscancer-associated fibroblastscolon cancerfibroblast activation proteinimmunosuppressive microenvironment

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Nanjing BenQ Medical Center, Nanjing, Jiangsu, China.
  • Department of Clinical Laboratory, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China, xzch.cn.

ORCID-Profile: Qian Ding, Qingyan Lu

Zitieren

APA

Ding, Q., & Lu, Q. (2026). FAP as a Clinical Biomarker: FAP+ CAFs Orchestrate an Immunosuppressive Stem Cell Niche via the COL1A1/2‐CD44 Axis in Colon Cancer. Stem Cells International, 2026(1). https://doi.org/10.1155/sci/4678145

Vancouver

Ding Q, Lu Q. FAP as a Clinical Biomarker: FAP+ CAFs Orchestrate an Immunosuppressive Stem Cell Niche via the COL1A1/2‐CD44 Axis in Colon Cancer. Stem Cells International. 2026;2026(1). doi:10.1155/sci/4678145

BibTeX
@article{Ding2026,
  author = {Ding, Qian and Lu, Qingyan},
  title = {FAP as a Clinical Biomarker: FAP+ CAFs Orchestrate an Immunosuppressive Stem Cell Niche via the COL1A1/2‐CD44 Axis in Colon Cancer},
  journal = {Stem Cells International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/sci/4678145}
}
Kostenlos starten →